Skip Navigation LinksHome > August 15, 2014 - Volume 66 - Issue 5 > WHO Multicenter Evaluation of FACSCount CD4 and Pima CD4 T-C...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0000000000000214
Implementation and Operational Research: Clinical Science

WHO Multicenter Evaluation of FACSCount CD4 and Pima CD4 T-Cell Count Systems: Instrument Performance and Misclassification of HIV-Infected Patients

Wade, Djibril MSc*,†,‡; Daneau, Géraldine PhD*; Aboud, Said PhD§; Vercauteren, Gaby H. PhD; Urassa, Willy S. K. PhD; Kestens, Luc PhD*,‡

Open Access
Supplemental Author Material
Collapse Box

Abstract

Background: CD4+ T-cell counts are used to screen and follow-up HIV-infected patients during treatment. As part of the World Health Organization prequalification program of diagnostics, we conducted an independent multicenter evaluation of the FACSCount CD4 and the Pima CD4, using the FACSCalibur as reference method.

Methods: A total of 440 paired capillary and venous blood samples were collected from HIV-infected patients attending the HIV outpatient clinic in Antwerp, Belgium, and the HIV care and treatment center in Dar es Salam, Tanzania. Capillary blood was run on Pima analyzer, whereas venous blood was analyzed on FACSCount, Pima, and FACSCalibur instruments. Precision and agreement between methods were assessed.

Results: The FACSCount CD4 results were in agreement with the FACSCalibur results with relative bias of 0.4% and 3.1% on absolute CD4 counts and an absolute bias of −0.6% and −1.1% on CD4% in Antwerp and Dar es Salam, respectively. The Pima CD4 results were in agreement with the FACSCalibur results with relative bias of −4.1% and −9.4% using venous blood and of −9.5% and −0.9% using capillary blood in Antwerp and Dar es Salam, respectively. At the threshold of 350 cells per microliter, the FACSCount CD4 and Pima CD4 using venous and capillary blood misclassified 7%, 9%, and 13% of patients, respectively.

Conclusions: The FACSCount CD4 provides reliable CD4 counts and CD4% and is suitable for monitoring adult and pediatric HIV patients in moderate-volume settings. The Pima CD4 is more suitable for screening eligible adult HIV patients for antiretroviral treatment initiation in low-volume laboratories.

© 2014 by Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.